Ingrid Glimelius

About

Ingrid Glimelius is a leading oncologist and researcher whose work is reshaping the treatment landscape for testicular cancer, particularly seminoma. Her primary research focus is on reducing long-term treatment toxicity while maintaining excellent survival outcomes. Glimelius is a key figure in the SWENOTECA (Swedish Norwegian Testicular Cancer Group), where she has championed the use of primary retroperitoneal lymph node dissection (RPLND) as an alternative to chemotherapy or radiotherapy for low-volume metastatic seminoma (stage IIA–IIC, ≤3cm). Her landmark 2024 study, with 19 citations, demonstrated that RPLND offers effective oncological control while sparing patients the significant long-term morbidities associated with cytotoxic treatments. This work, alongside her 2023 collaborative study with the Cologne group (7 citations), provides compelling evidence for a paradigm shift in clinical practice. Glimelius’s contributions are pivotal in the move toward de-escalation strategies in genitourinary oncology, directly impacting patient quality of life. Her research is highly cited and influential, marking her as a pioneer in surgical management for seminoma and a vital voice in the international testicular cancer community.

Research Focus

Key Achievements

Top Papers

1. 1
   Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience

   19 citations · 2024
2. 2
   Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.

   7 citations · 2023
3. 3
   MP33-04 THE EARLY RESULTS OF THE SWENOTECA (SWEDISH NORWEGIAN TESTICULAR CANCER GROUP) INTRODUCTION OF PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) IN SEMINOMA STAGE IIA-IIB ≤ 3cm

   3 citations · 2023

Key Collaborators

Contact & Links